Key result
High-density lipoprotein exerts anti-inflammatory and anti-atherogenic effects primarily by preventing the oxidative modification of proteins and lipids via paraoxonase 1 (PON1).
Answers are grounded in this paper and cite their sources.
This introductory review highlights that the atheroprotective role of HDL is largely driven by its paraoxonase 1 (PON1)-mediated antioxidant capacity rather than reverse cholesterol transport, suggesting PON1 activity may serve as a useful marker and therapeutic target in ASCVD.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Paul N. Durrington (2026) conducted an editorial in Atherosclerotic cardiovascular disease (ASCVD). High-density lipoprotein (HDL) and paraoxonase 1 (PON1) was evaluated. High-density lipoprotein exerts anti-inflammatory and anti-atherogenic effects primarily by preventing the oxidative modification of proteins and lipids via paraoxonase 1 (PON1).
Synapse has enriched 10 related papers. Consider them for comparative context: